Immunome (NASDAQ:IMNM) Shares Gap Up to $20.58

Immunome, Inc. (NASDAQ:IMNM) gapped up before the market opened on Monday . The stock had previously closed at $20.58, but opened at $21.72. Immunome shares last traded at $21.31, with a volume of 71,310 shares traded.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IMNM. Guggenheim began coverage on shares of Immunome in a research report on Monday. They issued a “buy” rating and a $35.00 price objective on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Wedbush increased their price objective on shares of Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Finally, SVB Leerink began coverage on shares of Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.67.

Immunome Stock Down 2.4 %

The company’s 50 day moving average is $23.31 and its 200 day moving average is $14.78. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.41 and a beta of 1.66.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently modified their holdings of IMNM. Renaissance Technologies LLC acquired a new position in shares of Immunome in the first quarter valued at about $80,000. First Republic Investment Management Inc. acquired a new stake in Immunome during the first quarter worth about $87,000. UBS Group AG grew its stake in Immunome by 1,049.9% during the third quarter. UBS Group AG now owns 15,271 shares of the company’s stock worth $68,000 after buying an additional 13,943 shares in the last quarter. Vanguard Group Inc. grew its stake in Immunome by 0.8% during the third quarter. Vanguard Group Inc. now owns 373,685 shares of the company’s stock worth $1,659,000 after buying an additional 3,149 shares in the last quarter. Finally, Natixis acquired a new stake in Immunome during the fourth quarter worth about $25,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.